OPTION CARE HEALTH INC
OPCHNASDAQTrading Snapshot
- Day Range
- $31.25 β $31.32
- 52-Week Range
- $18.01 β $36.80
- Volume (shares)
- 2,839,130
- Avg Volume (shares)
- β
- Shares Outstanding
- 149.8M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $5.65B
- Last Q Revenue
- $1.44B
- P/E Ratio
- 23.5
- P/S Ratio
- 0.8x
- EPS (TTM)
- $1.35
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β6.0%
OPTION CARE HEALTH INC
OPCHAbout OPTION CARE HEALTH INC
Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 20, 2026Insiders may stand to receive substantial financial benef

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq β SLN), Option Care Health, Inc. (Nasdaq β OPCH), RXO Inc. (NYSE β RXO), Sangoma Technologies Corporation (Nasdaq β SANG)
BALA CYNWYD, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

Are DSGR, OPCH, PRTH, UTZ Obtaining Fair Deals for their Shareholders?
Are DSGR, OPCH, PRTH, UTZ Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 18, 2026Insiders may stand to receive substantial financial bene

Cencora (NYSE:COR) and Option Care Health (NASDAQ:OPCH) Financial Contrast
Cencora (NYSE: COR - Get Free Report) and Option Care Health (NASDAQ: OPCH - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of thei

OPCH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Option Care Health to CD&R and McKesson
MONSEY, N.Y., Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Option Care Health, Inc. (NASDAQ: OPCH) (βOPCHβ) to CD&R and McKesson Corporation

Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene